CLINICAL_TRIALS
trial_result
· 2017-02-27
Clinical Trial Update: Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever [Phase 1]
Summary
Phase 1 safety and immunogenicity study of TDV, a live attenuated tetravalent dengue vaccine, completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Inviragen Inc. | Conditions: Dengue Fever | Phase 1 | Status: COMPLETED | Results posted: 2017-02-27